Ibrutinib for treating Waldenstrom's macroglobulinaemia - guidance (TA491)

National Institute for Health and Care Excellence - NICE
Publication date:
22 November 2017


Evidence-based recommendations on ibrutinib (Imbruvica) for Waldenstrom’s macroglobulinaemia in adults.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: More evidence on ibrutinib is being collected, until September 2020. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.

Commercial arrangement

There is a managed access agreement, which includes a commercial access agreement for ibrutinib. Contact janssenukcustomerservices@its.jnj.com for details.